We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -1.41% | 7.01 | 6.99 | 7.04 | 7.03 | 6.96 | 7.00 | 626,362 | 21:13:57 |
From Jun 2022 to Jun 2024
By Dean Seal
Bayer has tapped the head of its pharmaceuticals business for the Americas to take over all U.S. operations.
The German pharmaceutical and agricultural giant said Wednesday that Sebastian Guth will retain his leadership over the pharmaceuticals arm for the U.S. and Canada while ascending to the role of president for Bayer U.S.
Oversight of Bayer's pharmaceutical business in Latin America will shift to Heike Prinz, the head of commercial operations for the company's pharmaceutical operations in Europe, the Middle East and Africa.
The leadership shuffles follows the departure of former Bayer U.S. President Patrick Lockwood-Taylor, who left earlier this month to become CEO of Perrigo.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 21, 2023 10:38 ET (14:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
